Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Raytheon Technologies Corp — how do they compare? Hinge Health Inc. Class A Common Stock trades at $103.96 (market cap $8.48B), while Raytheon Technologies Corp trades at $188.47 (market cap $246.67B). The key difference: Raytheon Technologies Corp is far larger — about 29.1× Hinge Health Inc. Class A Common Stock's market cap, and Raytheon Technologies Corp pays a 1.6% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Raytheon Technologies Corp for 78 Days on average.
| HNGE | RTX | |
|---|---|---|
Market Cap | $8.48B | $246.67B |
Volume | 879,799 | 4,726,714 |
Sector | Health | Industrials |
52-Week High | $105.14 | $225.49 |
52-Week Low | $31.17 | $157.00 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $8.10B | $277.22B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
RTX trades at $183.02, down 1.95% today, amid a bearish technical signal. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.89 exceeding the $1.66 estimate. Revenue grew to $88.60 billion in 2025, and the net income margin improved to 7.59%. A robust $289 billion backlog and positive defense budget trends underpin growth prospects, though elevated debt levels and a high P/E ratio of 32.22 present valuation concerns.
The outlook remains positive given analyst consensus, with a $233.55 price target implying significant upside. Key opportunities include sustained defense demand and commercial aerospace recovery. Risks involve execution on the large backlog, interest expense from debt, and geopolitical uncertainties affecting defense spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
